We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Screening for Breast Cancer Benefits High-Risk, Underserved Women

By HospiMedica International staff writers
Posted on 06 Oct 2011
Using breast magnetic resonance imaging (MRI) screenings among targeted, high-risk, underserved women considerably decreases diagnostic cost and increases patient compliance rates with follow-up compared to using just general risk mammography screenings. More...


However, a caveat to these findings was that the cost of a MRI scan was reduced from an average of US$3,500 to $649 by a grant specific to the study. Cost per diagnosis was $37,375 for mammography compared to $21,561 for MRI at the grant-based rate, according to the researchers. “What we need is to lower the cost of MRI, and maybe that will happen as we do more of them,” said lead researcher Anne C. Ford, MD, assistant professor in obstetrics and gynecology at Duke University Medical Center (Durham, NC, USA).

Early findings of the study, conducted by Dr. Ford and colleagues from 2004 to 2011, were presented at the Fourth American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities, held in Washington DC (USA) from September 18-21, 2011.

The researchers compared breast cancer mammography screening in 299 general risk, underserved women to MRI screening in 299 high-risk, underserved women. Women with abnormal mammogram or abnormal breast MRI underwent ultrasound, ultrasound guided biopsy and/or stereotactic biopsy for mammogram cases, and/or MRI-guided biopsy for MRI cases.

Results showed that mammographic screenings detected one breast cancer case, while MRI screenings detected nine cases. Benign breast/total biopsies were found in 88% of mammographic screening cases and in 78% of MRI cases. “In an underserved population, using this model, it is cost effective to screen with MRI because we found more breast cancers with MRI than we did with mammography in this population,” Dr. Ford said. “If you truly target high-risk women with MRIs, you can find the cancers, and you can find them early.”

Moreover, compliance with follow-up in mammographic screenings was 75% and 90% in MRI screenings. Critical to those findings was the utilization of a breast navigation team, which recruited study participants from the general population at health and screening fairs in central North Carolina (USA), according to Dr. Ford. “The navigation team was key in helping the women--and these are all uninsured or under-insured women--negotiate the medical center,” she said.

Related Links:
Duke University Medical Center



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Rapid Sepsis Test
SeptiCyte RAPID
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.